Cargando…

Manufacture of Immunoglobulin Products for Patients with Primary Antibody Deficiencies – The Effect of Processing Conditions on Product Safety and Efficacy

Early preparations of immunoglobulin (Ig) manufactured from human plasma by ethanol (Cohn) fractionation were limited in their usefulness for substitution therapy in patients with primary antibody deficiencies (PAD), as Ig aggregates formed during manufacture resulted in severe systemic reactions in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farrugia, Albert, Quinti, Isabella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274962/ https://www.ncbi.nlm.nih.gov/pubmed/25566269 http://dx.doi.org/10.3389/fimmu.2014.00665

Ejemplares similares

Editorial: Immunoglobulin Therapy in the 21st Century – the Dark Side of the Moon
por: Farrugia, Albert, et al.
Publicado: (2015)

Editorial: The Complexity of Primary Antibody Deficiencies
por: Quinti, Isabella, et al.
Publicado: (2021)

On the Dark Side of Therapies with Immunoglobulin Concentrates: The Adverse Events
por: Späth, Peter J., et al.
Publicado: (2015)

IGA Antibody Induced by Immunization With Pneumococcal Polysaccharides Is a Prognostic Tool in Common Variable Immune Deficiencies
por: Pulvirenti, Federica, et al.
Publicado: (2020)

Modulatory Effects of Antibody Replacement Therapy to Innate and Adaptive Immune Cells
por: Quinti, Isabella, et al.
Publicado: (2017)

Adequate Patient’s Outcome Achieved with Short Immunoglobulin Replacement Intervals in Severe Antibody Deficiencies
por: Milito, Cinzia, et al.
Publicado: (2014)

Efficacy, Safety and Tolerability of a New 10% Intravenous Immunoglobulin for the Treatment of Primary Immunodeficiencies
por: Perez, Elena E., et al.
Publicado: (2021)

The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency
por: Quinti, Isabella, et al.
Publicado: (2022)

Primary Immune Deficiency: Patients’ Preferences for Replacement Immunoglobulin Therapy
por: Gonzalez, Juan Marcos, et al.
Publicado: (2022)

Subcutaneous Immunoglobulin for Antibody Deficiency in Antineutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis
por: Kant, Sam, et al.
Publicado: (2019)

Manufacturing Natural Killer Cells as Medicinal Products
por: Chabannon, Christian, et al.
Publicado: (2016)

Enhanced Antibody Production in Clever-1/Stabilin-1–Deficient Mice
por: Dunkel, Johannes, et al.
Publicado: (2018)

Efficacy and Safety of a Multistrain Probiotic Formulation Depends from Manufacturing
por: Trinchieri, Vito, et al.
Publicado: (2017)

Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese
por: Kan, Andy Ka Chun, et al.
Publicado: (2022)

Update on Infections in Primary Antibody Deficiencies
por: Demirdag, Yesim Yilmaz, et al.
Publicado: (2021)

Is Dosing of Therapeutic Immunoglobulins Optimal? A Review of a Three-Decade Long Debate in Europe
por: Kerr, Jacqueline, et al.
Publicado: (2014)

Viral Safety Issues in the Production and Manufacturing of Human Immunoglobulin Preparations from Equine Plasma/Serum
por: Mashin, V. V., et al.
Publicado: (2022)

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies
por: Kobayashi, Roger H., et al.
Publicado: (2019)

Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery
por: Couto, Pedro S., et al.
Publicado: (2023)

Longitudinal Study on Health-Related Quality of Life in a Cohort of 96 Patients with Common Variable Immune Deficiencies
por: Tabolli, Stefano, et al.
Publicado: (2014)

Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig(®)]) in the treatment of patients with primary immunodeficiencies
por: Kobayashi, Roger H., et al.
Publicado: (2022)

Process Development for Adoptive Cell Therapy in Academia: A Pipeline for Clinical-Scale Manufacturing of Multiple TCR-T Cell Products
por: Silva, Daniela Nascimento, et al.
Publicado: (2022)

Deficiency in the production of antibodies to lipids correlates with increased lipid metabolism in severe COVID-19 patients
por: Piédrola, Ignacio, et al.
Publicado: (2023)

Editorial: Translating NK cell scientific research to clinical product manufacturing
por: Ullrich, Evelyn, et al.
Publicado: (2023)

The Evolution of the Safety of Plasma Products from Pathogen Transmission—A Continuing Narrative
por: Farrugia, Albert
Publicado: (2023)

Health-Related Quality of Life and Patients’ Empowerment in the Health Care of Primary Immune Deficiencies
por: Quinti, Isabella, et al.
Publicado: (2017)

Analysis of Specific IgG Titers Against Tick-Borne Encephalitis in Patients with Primary Antibody Deficiency Under Immunoglobulin Substitution Therapy: Impact of Plasma Donor Origin
por: Goldacker, Sigune, et al.
Publicado: (2015)

Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP)
por: Hong, Junshik, et al.
Publicado: (2018)

Bronchiectasis in Primary Antibody Deficiencies: A Multidisciplinary Approach
por: Wall, Luke A., et al.
Publicado: (2020)

Oocytes could rearrange immunoglobulin production to survive over adverse environmental stimuli
por: Wang, Yang, et al.
Publicado: (2022)

Deficiency of STING Promotes Collagen-Specific Antibody Production and B Cell Survival in Collagen-Induced Arthritis
por: Tansakul, Mookmanee, et al.
Publicado: (2020)

Hypomorphic Mutations in the BCR Signalosome Lead to Selective Immunoglobulin M Deficiency and Impaired B-cell Homeostasis
por: Geier, Christoph B., et al.
Publicado: (2018)

Fatigue Is Common in Immunoglobulin G Subclass Deficiency and Correlates With Inflammatory Response and Need for Immunoglobulin Replacement Therapy
por: Wågström, Per, et al.
Publicado: (2022)

Blood-Borne ST6GAL1 Regulates Immunoglobulin Production in B Cells
por: Irons, Eric E., et al.
Publicado: (2020)

S1PR(4) deficiency results in reduced germinal center formation but only marginally affects antibody production
por: Riese, Janik, et al.
Publicado: (2022)

CAR-T manufactured from frozen PBMC yield efficient function with prolonged in vitro production
por: Abraham-Miranda, Julieta, et al.
Publicado: (2022)

Product/Process Fingerprint in Micro Manufacturing
por: Tosello, Guido
Publicado: (2019)

Lack of Gut Secretory Immunoglobulin A in Memory B-Cell Dysfunction-Associated Disorders: A Possible Gut-Spleen Axis
por: Carsetti, Rita, et al.
Publicado: (2020)

Measurement of Typhim Vi IgG as a Diagnostic Tool to Determine Anti-polysaccharide Antibody Production Deficiency in Children
por: Guevara-Hoyer, Kissy, et al.
Publicado: (2019)

Endocrine Disorders Are Prominent Clinical Features in Patients With Primary Antibody Deficiencies
por: Coopmans, Eva C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aq5q72s4rj6hvaorj6dn6amjae